Serum levels of interleukin 17F (IL-17F) were not associated with the response to treatment with interferon beta-1b in patients with relapsing-remitting multiple sclerosis, researchers found.
There were no significant differences in IL-17F concentrations when comparing patients with less versus more disease activity, those with no versus some disease activity, or clinically-defined responders versus nonresponders, according to Hans-Peter Hartung, MD, of Heinrich-Heine-Universität in Düsseldorf, Germany, and colleagues.
Information provided by:
Cherie C. Binns RN BS MSCN
USE OUR SHARE LINKS at the top of this page - to provide this article to others